Flindr Therapeutics Raises €20M in Series A Financing
Summary
Led by CEO Maarten Ligtenberg, Flindr Therapeutics is a pre-clinical biotech company developing precision oncology treatments. This approach involves reverse-translating the heterogeneity in tumor-specific and host-specific factors, as commonly seen in patients in the clinic, into lab-based biological models to screen for and select the most important drug targets involved in patient clinical response. Flindr’s lead program is a first-in-class small molecule inhibitor of RNF31 (also known as HOIP), a protein-stabilizing E3 ubiquitin ligase which is aberrantly activated in solid and hematological malignancies. The company has already obtained highly promising activity for the drug candidate in preclinical ovarian cancer and B-cell lymphoma models, and identified biomarkers which will help select patients most likely to respond to treatment with RNF31 inhibitors. The backing of this highly regarded investor syndicate is a strong validation of our unique approach and the potential of our pipeline.”